Latest Content

Basics of Squamous Cell Bladder Cancer

November 25th 2025, 5:00pm

By Alex Biese

Article

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

AVZO-103 Wins FDA Designation for Previously Treated Urothelial Cancer

November 25th 2025, 4:00pm

By Ryan Scott

Article

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.

Expert Explains Recent Advances in Early Stage Lung Cancer Surgery

November 25th 2025, 2:00pm

By Spencer Feldman

Article

An expert explains how minimally invasive surgery helps remove smaller lung areas with quicker recovery and improves outcomes for patients with early-stage lung cancer.

How I Navigate Grief and the Holidays After Cancer Loss

November 24th 2025, 10:00pm

By Georgia Hurst

Article

I share how the holidays feel different after loss and how grief, love and gratitude can coexist as I navigate this season with gentleness and care.

How New Therapies Are Changing the Game for Small Cell Lung Cancer

November 24th 2025, 9:00pm

By Spencer Feldman

Article

Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.

SANRECO Trial Explores Divesiran for Polycythemia Vera Treatment

November 24th 2025, 8:00pm

By Alex Biese

Article

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Voranigo is Safe and Tolerable in High-Grade IDH-Mutant Gliomas

November 24th 2025, 5:58pm

By Ryan Scott

Article

Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

Sac-TMT Combo Shows Benefit in Advanced Lung Cancer Treatment

November 24th 2025, 5:00pm

By Spencer Feldman

Article

Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

Imbruvica Plus Drug Combo Shows Strong Responses in Newly Diagnosed PCNSL

November 24th 2025, 4:05pm

By Ashling Wahner

Article

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Expert Advice and Resources for Patients with Neuroendocrine Tumors

November 24th 2025, 2:00pm

By Dr. Pamela L. Kunz

Video

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Addressing Common Talquetamab Misunderstandings

November 24th 2025, 1:12pm

By Samantha Shenoy, MSN, NP

Video

Panelists discuss how healthcare providers and patients should understand that talquetamab's unique side effects are temporary and resolve over time even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.

Advice for the Caregiver: Be a Patient Advocate

November 24th 2025, 1:11pm

By Samantha Shenoy, MSN, NP

Video

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, attend all appointments, stay informed about myeloma research, and serve as active advocates who can communicate with healthcare teams when patients cannot.

Advice for the Patient Starting Treatment With Talquetamab

November 24th 2025, 1:10pm

By Samantha Shenoy, MSN, NP

Video

Panelists discuss how patients beginning talquetamab should maintain a positive attitude, prepare thoroughly with educational materials, and understand that while initial side effects can be challenging, they are temporary and manageable with proper preparation and support.

Managing Taste Changes and Weight Loss During Talquetamab Treatment

November 24th 2025, 1:09pm

By Samantha Shenoy, MSN, NP

Video

Panelists discuss how patients can maintain nutrition during talquetamab treatment by focusing on texture and food presentation when taste is impaired, using high-calorie options, and remembering that taste changes and dry mouth are temporary side effects that improve over time.

Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab

November 24th 2025, 1:08pm

By Samantha Shenoy, MSN, NP

Video

Panelists discuss how specific talquetamab-related side effects like skin peeling, nail changes, and rashes can be effectively managed through targeted interventions including topical treatments, protective measures, and preventive strategies tailored to the drug's unique toxicity profile.